Changshan Pharmaceutical (300255.SZ) released its first half-year performance, with a net loss attributable to the parent company of 29.089 million yuan, narrowing by 37.98%.

Financial news from CITIC Securities APP, Changshan Pharmaceutical (300255.SZ) released its 2025 interim report. The company's operating income was 492 million yuan, a decrease of 13.42% year-on-year. The net loss attributable to shareholders of the listed company was 29.089 million yuan, a decrease of 37.98% year-on-year. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 30.2589 million yuan, a decrease of 43.62% year-on-year. Basic loss per share was 0.03 yuan.